Skip to content
lifestyle.ucconnection.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Intellia Therapeutics, Inc.
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
October 29, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 28, 2026
Intellia Therapeutics Appoints Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer
October 13, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Lonvo-z FDA Priority Review for HAE | Intellia Therapeutics
September 8, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
September 4, 2026
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
September 4, 2026
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
1
2
Next Page
→